Latest News and Press Releases

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...

AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:...

AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites...

AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne,...